Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study.

Anaxirone, a rationally synthesised triepoxide derivative, was given to 46 patients with metastatic colorectal cancer. Good risk patients received 800 mg/m2 as a rapid intravenous injection every 4 weeks, whereas poor risk patients received 650 mg/m2. Of 46 patients, 45 were evaluable for toxicity and 42 for efficacy analysis. There were 37/45 patients with poor risk, showing no difference in toxicity as compared to good risk patients. The major toxic effect was myelosuppression with 34% of all patients experiencing grade 3 or 4 leucopenia; thrombocytopenia was less frequent. Locoregional phlebitis occurred in 66% of the patients. There was no objective tumour response to anaxirone in 42 evaluable patients. Only 4 patients achieved stabilisation of the disease lasting maximally up to 248 days. Anaxirone is inactive in metastatic colorectal cancer.
AuthorsE E Holdener, M Clavel, C Sessa, W ten Bokkel Huinink, P Siegenthaler, C Ludwig, O Klepp, G Renard, G Decoster, H M Pinedo
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 30A Issue 3 Pg. 394-5 ( 1994) ISSN: 0959-8049 [Print] ENGLAND
PMID8204365 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • Antineoplastic Agents
  • Triazoles
  • anaxirone
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Colorectal Neoplasms (drug therapy)
  • Female
  • Humans
  • Leukopenia (chemically induced)
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Thrombocytopenia (chemically induced)
  • Treatment Outcome
  • Triazoles (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: